{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:15Z","timestamp":1786997955297,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.075","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:38:12Z","timestamp":1568014692000},"page":"6500-6509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area"],"prefix":"10.1016","volume":"37","author":[{"given":"W.A.","family":"Keitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Diemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bethony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Plieskatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Deye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2019.08.075_b0005","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1371\/journal.pntd.0000485","article-title":"Schistosomiasis in Africa: an emerging tragedy in our new global health decade","volume":"3","author":"Hotez","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.08.075_b0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1586\/14760584.7.6.745","article-title":"Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis","volume":"7","author":"Hotez","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.075_b0015","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2017 Sep 16; 390 (10100):1211-1259."},{"issue":"7","key":"10.1016\/j.vaccine.2019.08.075_b0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.075_b0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0035-9203(03)90057-5","article-title":"No effect of recall period length on prevalence of self-reported haematuria in Schistosoma haematobium-endemic areas","volume":"97","author":"van der Werf","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.075_b0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/08820139209069381","article-title":"Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control","volume":"21","author":"Butterworth","year":"1992","journal-title":"Immunol Invest"},{"key":"10.1016\/j.vaccine.2019.08.075_b0035","doi-asserted-by":"crossref","unstructured":"M\u00e4der P, Rennar GA, Ventura AMP, Grevelding CG, Schlitzer M. Chemotherapy for fighting schistosomiasis: past, present and future. Chem Med Chem. 2018 Sep 13. http:\/\/doi.org\/10.1002\/cmdc.201800572. [Epub ahead of print] Review. PMID: 30212614.","DOI":"10.1002\/cmdc.201800572"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.075_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/CMR.00046-07","article-title":"Current status of vaccines for schistosomiasis","volume":"21","author":"McManus","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.075_b0045","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1371\/journal.pntd.0000071","article-title":"Eliminating lymphatic filariasis, onchocerciasis, and schistosomiasis from the Americas: breaking a historical legacy of slavery","volume":"1","author":"Lammie","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2019.08.075_b0050","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1074\/jbc.M113.531558","article-title":"Solution structure, membrane interactions, and protein binding partners of the tetraspanin Sm-TSP-2, a vaccine antigen from the human blood fluke Schistosoma mansoni","volume":"289","author":"Jia","year":"2014","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2019.08.075_b0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nm1430","article-title":"Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis","volume":"12","author":"Tran","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.075_b0060","doi-asserted-by":"crossref","first-page":"e1000840","DOI":"10.1371\/journal.ppat.1000840","article-title":"Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover","volume":"6","author":"Tran","year":"2010","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2019.08.075_b0065","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.4161\/hv.25787","article-title":"Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis","volume":"9","author":"Curti","year":"2013","journal-title":"Hum Vaccin Immunother."},{"issue":"11","key":"10.1016\/j.vaccine.2019.08.075_b0070","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.4161\/hv.25788","article-title":"Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis","volume":"9","author":"Cheng","year":"2013","journal-title":"Hum Vaccin Immunother."},{"key":"#cr-split#-10.1016\/j.vaccine.2019.08.075_b0075.1","doi-asserted-by":"crossref","unstructured":"Diemert DJ, Freire J, Valente V, Fraga CG, Talles F, Grahek S, Campbell D, Jariwala A, Periago MV, Enk M, Gazzinelli MF, Bottazzi ME, Hamilton R, Brelsford J, Yakovleva A, Li G, Peng J, Correa-Oliveira R, Hotez P, Bethony J. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2017 May 2","DOI":"10.1371\/journal.pntd.0005574"},{"key":"#cr-split#-10.1016\/j.vaccine.2019.08.075_b0075.2","doi-asserted-by":"crossref","unstructured":"11(5):e0005574. http:\/\/doi.org\/10.1371\/journal.pntd.0005574. eCollection 2017 May. PMID: 28464026.","DOI":"10.1371\/journal.pntd.0005574"},{"key":"#cr-split#-10.1016\/j.vaccine.2019.08.075_b0080.1","doi-asserted-by":"crossref","unstructured":"Brelsford JB, Plieskatt JL, Yakovleva A, Jariwala A, Keegan BP, Peng J, Xia P, Li G, Campbell D, Periago MV, Correa-Oliveira R, Bottazzi ME, Hotez PJ, Diemert D, Bethony JM. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1\/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis. 2017 Feb 13","DOI":"10.1371\/journal.pntd.0005385"},{"key":"#cr-split#-10.1016\/j.vaccine.2019.08.075_b0080.2","doi-asserted-by":"crossref","unstructured":"11(2): e0005385. http:\/\/doi.org\/10.1371\/journal.pntd.0005385. eCollection 2017 Feb. PMID: 28192438.","DOI":"10.1371\/journal.pntd.0005385"},{"issue":"10","key":"10.1016\/j.vaccine.2019.08.075_b0085","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1586\/erv.10.107","article-title":"Potency testing for the experimental Na-GST-1 hookworm vaccine","volume":"9","author":"Jariwala","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"26","key":"10.1016\/j.vaccine.2019.08.075_b0090","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.vaccine.2016.03.079","article-title":"Advancine a vaccine to prevent human schistosomiasis","volume":"34","author":"Merrifield","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2019.08.075_b0095","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2307\/2531147","article-title":"Random-effects models for serial observations with binary response","author":"Stiratelli","year":"1984","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.075_b0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2307\/3001775","article-title":"Tests for linear trends in proportions and frequencies","volume":"11","author":"Armitage","year":"1955","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2019.08.075_b0105","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Pollysaccharide conjugate vaccine protein carriers as a 'neglected valency'. Potential limitations","volume":"35","author":"Broker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.075_b0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-019-0121-9","article-title":"Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230","volume":"4","author":"Scaria","year":"2019","journal-title":"NPH Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.075_b0115","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1007\/s00436-018-6063-8","article-title":"Molecular characterization, expression profile, and preliminary evaluation of diagnostic potential of CD63 in Schistosoma japonicum","volume":"117","author":"Wang","year":"2018","journal-title":"Parasit Res"},{"key":"10.1016\/j.vaccine.2019.08.075_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S0022149X09308020","article-title":"Schistosomes in the southwest United States and their potential for causing cercarial dermatitis or \u201cswimmer\u2019s itch\u201d","volume":"83","author":"Brandt","year":"2009","journal-title":"J Helminthol"},{"key":"10.1016\/j.vaccine.2019.08.075_b0125","unstructured":"World Health Organization. Schistosomiasis and soil-transmitted helminthiases: numbers of people treated in 2017. Weekly Epidemiol Rec. 14 Dec 2018; 93(50): 681-92. https:\/\/www.who.int\/wer\/2018\/wer9350\/en\/."},{"key":"10.1016\/j.vaccine.2019.08.075_b0130","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1789-858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.075_b0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13071-017-2227-0","article-title":"Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities","volume":"10","author":"Stylianou","year":"2017","journal-title":"Parasit Vectors"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:01Z","timestamp":1759401541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1931151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":29,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X1931151X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}